CAVA Group Has Lost 37% in 6 Months: Melius Sees 82% Upside
CAVA Group's shares fell 37% over six months, partly due to a Cyclospora outbreak. Melius Research upgraded it to Buy with a $95 target, 82% above the Oct. 7 close, citing strong fundamentals and overreaction to recent issues. Analysts expect EPS growth to resume in 2027. CAVA trades at 78x forward earnings, below its 3-year average.
How this was made
The 30-second read
Why it matters
The analyst upgrade provides a new catalyst that could shift the stock's trajectory.
Market read
Analyst upgrade with a sizable price target increase may prompt buying activity in CAVA and related restaurant stocks.
What to watch
Potential lingering impact of the Cyclospora outbreak on same‑restaurant sales could curb upside.
Background
CAVA Group reported Q2 same‑restaurant sales growth but kept FY guidance unchanged amid a Cyclospora outbreak.
Ticker impact
Melius Research upgraded CAVA to Buy with a $95 price target, 82% above the current price.
likely upward pressure as traders price in the new target
The upgrade and higher target provide a fresh catalyst for buying interest.
Market effects
Positive sentiment may lift other fast‑casual restaurant stocks.
US equity markets could see modest gains in consumer discretionary.
Limited to US markets; no direct global effect.
Counterpoint
The upgrade may be overly optimistic given flat FY guidance and high valuation multiples.
Key entities
- analystMelius Research
Upgraded CAVA to Buy and raised price target.
- companyCAVA Group
Restaurant operator with recent sales slowdown.
